CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2020—Biocare Medical launched seven novel IVD IHC antibody markers for clinical diagnostics and research applications. This launch focuses on several immuno-oncology markers, critical in aiding early-stage cancer drug developments and patient treatment.
The company redeveloped its S100 protein antibody and released one mouse monoclonal and five novel rabbit monoclonal antibodies in the immuno-oncology space: CTLA-4 [CAL49], GITR [CAL8], LAG3 [CAL26], PD-1 [CAL20], CD22 (M) [BLCAM/1796], and E-cadherin [CDH1/2208R].
Pages: 1 2